Merck's $10.8B Calif. Biotech Buy Goes Unchallenged By FTC
The 30-day deadline for the Federal Trade Commission to review Merck's $10.8 billion purchase of biotechnology company Prometheus has passed without challenge, according to a filing with the U.S. Securities and...To view the full article, register now.
Already a subscriber? Click here to view full article